The Chemours Company (CC) — Available-Data Snapshot

We don't publish a discounted-cash-flow fair value for The Chemours Company (CC) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, CC trades at a recent price of $13.28, a market capitalisation of about $1,998,903,040, sitting 16% of the way up its 52-week range ($10.44–$28.67), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing CC's trading multiples against a sector benchmark. Here that gives Fwd P/E of 7.7× (cheaper than the peer median of 20.0×); P/B of 12.9× (richer than the peer median of 4.9×); P/S of 0.3× (cheaper than the peer median of 4.9×); EV/EBITDA of 11.1× (cheaper than the peer median of 19.0×); Dividend yield of 2.6% (cheaper than the peer median of 1.0%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. CC shows a price-to-book (P/B) of 12.89 and book value of $1.03 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. CC is in a down-trend (price below both its 50- and 200-day averages), trading -53.7% from its 52-week high. Over the past year the stock is +0.0%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.